Key Insights

Highlights

Success Rate

98% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

1.4%

1 terminated out of 72 trials

Success Rate

97.7%

+11.2% vs benchmark

Late-Stage Pipeline

6%

4 trials in Phase 3/4

Results Transparency

23%

10 of 43 completed with results

Key Signals

10 with results98% success

Data Visualizations

Phase Distribution

47Total
Not Applicable (6)
Early P 1 (2)
P 1 (17)
P 2 (18)
P 3 (2)
P 4 (2)

Trial Status

Completed43
Recruiting14
Active Not Recruiting7
Withdrawn3
Enrolling By Invitation2
Not Yet Recruiting2

Trial Success Rate

97.7%

Benchmark: 86.6%

Based on 43 completed trials

Clinical Trials (72)

Showing 20 of 20 trials
NCT04631224CompletedPrimary

Longitudinal Analysis of Oral Communication in Friedreich's Ataxia

NCT07731971Not Yet RecruitingPrimary

Digital Outcome Assessment Using AI Active Gaming and Motion Capture in Friedreich Ataxia

NCT07721025Phase 2RecruitingPrimary

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

NCT05874388Active Not RecruitingPrimary

Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia

NCT06628687RecruitingPrimary

A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies

NCT06681766Phase 1TerminatedPrimary

A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

NCT06953583Phase 3RecruitingPrimary

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

NCT06865482RecruitingPrimary

Clinical Course Of Disease In Participants With FA-CM

NCT04346238CompletedPrimary

Characterization of the Interruptions of the GAA Expansion and Study of Their Influence on the Severity of Friedreich's Ataxia

NCT04921930Phase 1CompletedPrimary

Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)

NCT06447025Phase 2RecruitingPrimary

An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

NCT06054893Phase 1Active Not RecruitingPrimary

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

NCT07013292RecruitingPrimary

Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia

NCT06623890RecruitingPrimary

A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

NCT04577352Phase 2CompletedPrimary

A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

NCT07508631RecruitingPrimary

Friedreich Ataxia Nerve Ultrasund

NCT05943002RecruitingPrimary

Patient-reported, Health Economic and Psychosocial Outcomes in Friedreich Ataxia

NCT05302271Phase 1RecruitingPrimary

Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

NCT02255435Phase 2CompletedPrimary

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

NCT06496451CompletedPrimary

Measurement of Frataxin mRNA in Biofluids

Scroll to load more

Research Network

Activity Timeline